


REPLACEMENT SHEET

1/29






FIG.2a




FIG.2b

FIG.3a




FIG.3b




FIG.3c




FIG.4a




FIG.4b




FIG.4c




FIG.5

The Distribution of Sex and Age of 100 Patients with A.I.F.

REPLACEMENT SHEET**5/29**

AGE	F	M	TOTAL
1-	2	3	5
11-	1		1
21-	3	5	8
31-	10	2	12
41-	16	7	23
51-	21	7	23
61-	20	1	21
71-	2		2
<u>TOTAL</u>	<u>75</u>	<u>25</u>	<u>100</u>

REPLACEMENT SHEET

6/29

FIG.6
ALF Dosage

	Patient No.	%	Dosage (cc/q4d) (minimum dose in cc that triggers blastogenesis)	Range	Mean
Normal	47	47		0.1	0.1
Build up	37	37		0.15-1.0	0.3
Dilution	16	16		0.01- 0.00001	0.05

FIG. 7

The Distribution of Time of Therapy

Months	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	14	11	7	7	6	10	6	4	7	20

Average therapy time: 7.4 ± 3.8 months

Range: 2-16 months

FIG.8

The Distribution of Dosage of Therapy

Dosage (cc)	2	3	4	5	6	7	8	9	10	11	>12
No. Patients	8	13	15	6	8	11	10	6	4	7	14

Average therapy

 6.44 ± 3.79 cc

Range: 2-25 cc

FIG.9

Scale of Clinical Symptoms and Signs of The Patient After ALF Treatment (Severity)

REPLACEMENT SHEET

9/29

Symptoms	Improvement No. %	No Charge No. %	Worsening No. %	Total Patients
Hypersensitive Reaction	63 63	33 33	1 1	100
Recurrent Infection	38 57	29 43	0 0	67
Fatigue	60 68	27 31	1 1	88
Lack of Concentration	43 54	36 46	0 0	79
Arthritis	19 44	23 54	1 2	43
G.I. Upset	29 40	43 60	0 0	72
Headache	28 44	33 53	2 3	64
Depression	42 58	30 42	0 0	72

REPLACEMENT SHEET**10/29**

FIG.10 Scale of Clinical Symptoms and Signs of
The Patient After ALF Treatment
(Frequency)

Symptoms	Improvement No. %	No Charge No. %	Worsening No. %	Total Patients
Hypersensitive Reaction	38 38	62 62	0 0	100
Recurrent Infection	26 39	41 61	0 0	67
Fatigue	38 43	50 57	0 0	88
Lack of Concentration	20 25	59 75	0 0	79
Arthritis	11 26	32 74	0 0	43
G.I. Upset	21 29	51 69	0 0	72
Headache	19 30	45 70	0 0	64
Depression	30 42	42 58	0 0	72

REPLACEMENT SHEET

11/29

The Changes of T&B Profile of 92 Patients Treated with ALF

	TOTAL LYMPHOCYTES	T _u	T ₄	T ₈	T ₄ /T ₈	B ₄
BEFORE	2112 _± 632	1624 _± 457	930 _± 45	439 _± 58	2.3 _± 0.8	188 _± 102
AFTER	2232 _± 678 *	1634 _± 544	1027 _± 297 **	478 _± 189 **	1.3 _± .4	171 _± 120

n = 92

* p<0.05 ** p<0.01

REPLACEMENT SHEET

12/29

FIG.12 T Lymphocyte Subsets of 92 Patients After A.I.F Treatment

TOTAL LYMPHOCYTES		T _u		T ₄		T ₁	
	NO. %	NO. %	NO. %	NO. %	NO. %	NO. %	NO. %
INCREASE	52 57	41 46		53 58		55 60	
DECREASE	40 43	51 54		39 42		37 40	
P	<0.05		>0.05		<0.05		<0.01

FIG. 13

CMI Results with ALF Effect CMI Scores (Number and Size, $\bar{x} \pm SD$)

NO. PATIENTS	BEFORE ALF	AFTER ALF	P
78	5.46 \pm 5.81	9.28 \pm 7.25	<0.001

CMI Positive Score (Number and Size) After ALF

NO. PATIENTS	%	P
INCREASE	58	74
NO CHANGE	9	12
DECREASE	11	14

The Relationship Between CMI and Clinical Symptom and Sign Improvement

IMPROVEMENT NO.	%	NO IMPROVEMENT NO.	%	P
CMI INCREASE	56	72	2	3
CMI NO CHANGE & DECREASE	14	18	6	8

13/29

REPLACEMENT SHEET

FIG. 14 Side Effects of ALF - (5% of Patients Can Not Tolerate ALF)

1. PAIN AND IRRITATION IN THROAT, BURNING IN THE EYES
2. NAUSEA
3. CHEST TIGHTNESS AND HEART PALPITATION
4. FLU-LIKE SYMPTOMS, HEADACHE, FATIGUE, CHILL.
5. INCREASE IN FOOD AND ODOR SENSITIVITY

FIG.15 190 Patients with ALF

	No.	%
Female	131	69
Male	59	31
Age:	2-76 years old	
Mean:	46.8	years old

REPLACEMENT SHEET

16/29

FIG. 16
ALF Dosage

Patient	Dosage (cc/q4d) (minimum dose in cc that triggers blastogenesis)	
No.	%	Range
Normal	88	46
Build up	84	44
Dilution	18	9

0.1 (1:10)
0.15-1.0 (1:10)
0.1 (1:20, 1:10²-1:10²)

FIG.17

The distribution of period of ALF therapy

Month	No. Patients	%
1-3	27	14.2
4-6	19	10.0
7-9	25	13.2
10-12	20	10.5
13-15	11	5.8
16-18	21	11.1
19-21	21	11.1
22-24	7	3.7
24-26	14	7.4
27-29	11	5.8
30-32	5	2.6
33-36	9	4.7

Average: 14.6 months (Range 1-37 months)

FIG. 18

The Distribution of dosage of ALF

Dosage (cc)	No. Patient	%
1-5	45	23.7
6-10	59	31.1
11-20	66	34.7
21-30	19	10
31-40	1	0.5
Total	190	100

Average: 11.27 (cc)

Range: 1-38 (cc)

FIG. 19

Scale of Clinical Symptoms and Signs of The C.S. Patient After ALF Treatment (Severity)

Symptoms	Improvement No. %	No Changes No. %	Worsening No. %	Total Patients
Hypersensitive Reaction	51 56.7	33 36.7	6 6.7	90
Recurrent Infection	33 50.8	27 41.5	5 7.7	65
Fatigue	58 71.6	17 20.99	6 7.4	81
Lack of Concentration	42 57.5	29 39.7	2 2.7	73
Arthritis	20 44.4	22 48.9	3 6.7	45
G.I. Upset	32 44.4	33 45.8	7 9.7	72
Headache	30 40.5	38 51.4	6 8.1	74
Depression	44 63.8	22 31.9	3 4.3	69

REPLACEMENT SHEET

20/29

FIG.20

Scale of Clinical Symptoms and Signs of The Patient After
ALF Treatment (frequency)

Symptoms	Improvement No. %	No Changes No. %	Worsening No. %	Total Patients
Hypersensitive Reaction	28 36.4	46 59.7	3 3.9	77
Recurrent Infection	27 46.6	27 46.6	4 6.9	58
Fatigue	36 47.4	37 48.7	3 3.9	76
Lack of Concentration	23 33.8	43 63.2	2 2.9	68
Arthritis	13 32.5	24 60.0	3 7.5	40
G.I.Upset	23 37.1	35 56.5	4 6.5	62
Headache	24 38.1	34 54.0	5 7.9	63
Depression	34 54.8	26 41.9	2 3.2	62

FIG.21

T & B Lymphocytes Parameters Changes After ALF

	(N)	Before (mean±SE)	After
WBC	25	4180±404.1**	4828±1164.6
Lymphs	34	1350 ±225.1**	1573.2±448.2
T11	32	989.4±198.1**	1182.6±331.2
T4	30	518.2±107.2**	689.5 ±200.1
Ratio of T4/T8	46	3.62± 0.99**	2.71± 1.04
T8	52	248.6±63.3**	354.3 ±124.9
B4	35	54.8±17.0**	121.3±78.7

**--P<0.01 (Change compared with before ALF therapy)

REPLACEMENT SHEET

22/29

FIG.22

T & B Lymphocytes parameters improvement after
ALF

	Patients No.	Improved No. (%)
WBC	25	18 72%
Lymphs	34	25 74%
T11	32	21 66%
T4	30	24 80%
Ratio of T4/T8	46	37 80.4%
T8	52	40 76.9%
B4	35	27 77%

FIG.23

CMI Improvements of 93 Patients with ALF

	Total No. of Antigen Responses
Increase	247*
Decrease	171
No change	233
Total	651

* P<0.001 compared with decrease

REPLACEMENT SHEET

24/29

FIG.24

Diagnosis

	<u>No.</u>	<u>%</u>
Chemical sensitivity	127	67
Food Sensitivity	106	56
Inhalant Sensitivity	84	44
EMF Sensitivity	9	5

REPLACEMENT SHEET

25/29

FIG.25

Diagnosis	No.	%
NS	104	54.7
C.V	53	27.9
G.I	59	31.1
G.U	15	7.9
M.S	107	56.3
EYE	4	2.1
Respiratory	87	45.8
Skin	22	11.6
Endocrine	24	12.6
Immune		
dysregulation	99	52.1
Chronic		
infection	42	22.1
Implant	7	3.7
Parasite	3	1.6
Carcinoma	3	1.6
Candidosis	8	4.2
HTV positive	1	0.5

FIG.26

50 Year Old White Female
HIV Positive

0.1cc every 4 doses			
CMI before -1	CMI after 3		
WBC - 3,500	10,000		
T ₁₁ 964	1359		
T ₁₁ % 54	73%		
T ₄ 149	750		
T ₄ % 8%	40%		
T ₈ 464	875		
T ₈ % 26	47%		
T ₄ /T ₃ .17	1.62		
B 36	93		
B% 2	5%		
Sx-fatigue, Energy			
neuropathy - gone			
Stomach pain - gone			
Non healing toe - gone			
Lesion for 2 yrs. - gone			
Took ALF for 5 months, then stopped			
All Sx exacerbated for 3 weeks.			
Restarted ALF and Sx disappeared			

B: Before ALF
 A: After ALF

FIG.27

PATIENTS WITH CANCER & ALF

46 y P Breast Cancer	59 y P Breast Cancer	59 y F Leukemia	84 y F para- thyroid tumor	67 y F para- thyroid tumor	42 y F Breast Cancer	42 y F Breast Cancer	63 y P Left Breast Mastectomy	23 y M Osteo- genic Sarcoma
3/1/95 9/3/96	6/1/95 7/21/95	10/20/94 2/7/95	3/25/96 1/9/97	10/10/94 5/30/95	10/10/94 5/30/95	10/31/96 1/10/97	4/8/96 9/24/96	
0.1cc 0.2cc	0.1cc	0.1cc	0.1cc	0.1cc	0.1cc	0.1cc	0.1cc	
90 doses	40	60	130	90	70	70	50	
Tetanus	B	A	B	A	B	B	B	A
Diphtheria	4	0	4	30	4	5	0	
Streptococcus	0	0	0	0	0	0	0	
Tuberculin	0	0	0	0	0	0	0	
Control	0	0	0	0	0	0	0	
Candida	0	0	0	0	0	0	0	
Trichophyton	0	0	0	0	0	0	0	
Proteus	0	4	0	4	0			

REPLACEMENT SHEET

27/29

REPLACEMENT SHEET

28/29

FIG. 28

FIG.28									
46 Y F Breast Cancer	59 Y F Breast Cancer	54 Y F Leuk- emia	67 Y F Par- thyroid tumor	42 Y F Breast Cancer	61 Y F Left Breast	23 Y M Osteo- Sarcoma			
NBC	B	A	B	A	B	A	B	A	B
5100	4300	4200	4200	22300†	7000	4700	5300	4500	6700
Lymphocytes	2550	1848		1538†	2590	1833	1305	1431	2412
Ly ⁺	50	40	33					27	
T ₀	1734	1478	1056		4923†	1868	1448	1188	
T ₁ +	68	62	80		32	76	79	66	72
T ₁	944	3184	832		2308†	1606	733	587	
T ₁ A	37	224	45		154	62†	40	36	30
T ₄	512	433	591		2616†	544	495	329	
T ₄ A	24	28	32		17	21	27	23	

REPLACEMENT SHEET

29/29

FIG. 29

T ₄ /T ₁		2.32		2.95†		1.5		1.03		1.8	
B ₁		15		0.794		1.41		0.94		1.03	
B ₁ %		332		205		120		1848†		104	
S: Severity		9		12		4		9		10	
F: Frequency		A		A		A		A		A	
Allergic		S		+		+		+		0	
P		P		+		+		+		0	
Headaches		S		0		0		0		0	
P		P		0		0		0		0	
Recurrent		S		4		4		4		0	
Infection		P		4		4		4		0	
Fatigue		S		4		4		4		0	
P		P		4		4		4		0	
Difficulty		S		4		4		4		0	
Concent.		P		0		0		0		0	
GI Upset		S		4		4		4		0	
P		P		4		4		4		0	
Depression		S		4		4		4		0	
P		P		4		4		4		0	
Arthritis		S		4		4		4		0	
P		P		4		4		4		0	